Ratings Runben Biotechnology Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 13/06/2024 BST			5-day change	1st Jan Change
18.34 ^CNY	-1.87%		-4.53%	+0.88%

04-24

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

With a 2024 P/E ratio at 25.83 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality